LUMICKS Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 217
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $93M
Latest Deal Amount
  • Investors
  • 13

LUMICKS General Information

Description

Developer and supplier of dynamic single-molecule and cell avidity analysis instruments designed to reveal unique molecular and cellular interactions. The company's instrument permits the disruptive techniques of live measurement and imaging of interactions at the single-molecule level, which is key for the prevention and cure of cancer and other diseases, enabling researchers with tools that provide unparalleled insight into the fundamental cause of disease and potential for drug optimization.

Contact Information

Website
www.lumicks.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Decision/Risk Analysis
Application Specific Semiconductors
Primary Office
  • Pilotenstraat 41
  • 1059 CH Amsterdam
  • Netherlands
+31 020 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LUMICKS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 15-Apr-2021 $93M 0000 Completed Generating Revenue
5. Later Stage VC Completed Generating Revenue
4. Grant 24-Jan-2017 00.000 Completed Generating Revenue
3. Grant 12-May-2015 Completed Startup
2. Grant 22-Jan-2015 $297K Completed Startup
1. Accelerator/Incubator Completed Startup
To view LUMICKS’s complete valuation and funding history, request access »

LUMICKS Patents

LUMICKS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210080394-A1 Methods and devices for determining a guest structure on a host structure Pending 05-Feb-2018 00000000000
EP-3749958-A1 Methods and devices for determining a guest structure on a host structure Pending 05-Feb-2018 00000000000
EP-3737756-A1 Methods and systems for supercoiling dna Pending 09-Jan-2018 0000000000
US-20200399688-A1 Method and system for supercoiling dna Pending 09-Jan-2018 000000000
US-11156513-B2 Method and system for optical force measurement Active 17-Nov-2017 G01L1/24 0
To view LUMICKS’s complete patent history, request access »

LUMICKS Executive Team (9)

Name Title Board Seat Contact Info
Olivier Heyning Co-Founder & Chief Executive Officer
Bauke van Rhijn Chief Financial Officer & Head of Product DSM
Gijs Oude Elberink Chief Operating Officer
Mattijs de Groot Chief Technology Officer
Andrea Candelli Co-Founder & Chief Scientific Officer
You’re viewing 5 of 9 executive team members. Get the full list »

LUMICKS Board Members (4)

Name Representing Role Since
Don Kania Ph.D Self Board Member 000 0000
Peter van den Broek Self Board Member 000 0000
Pieter Van der Meer Gilde Healthcare Partners Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

LUMICKS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LUMICKS Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
Irving Investors Growth/Expansion Minority 000 0000 000000 0
Lauxera Capital Partners Growth/Expansion Minority 000 0000 000000 0
Parian Global Management Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »